Brokerages predict that Ocular Therapeutix Inc (NASDAQ:OCUL) will report ($0.43) earnings per share for the current quarter, Zacks reports. Three analysts have issued estimates for Ocular Therapeutix’s earnings, with the highest EPS estimate coming in at ($0.41) and the lowest estimate coming in at ($0.47). Ocular Therapeutix reported earnings per share of ($0.42) in the same quarter last year, which would suggest a negative year-over-year growth rate of 2.4%. The firm is scheduled to announce its next earnings report on Thursday, March 5th.
On average, analysts expect that Ocular Therapeutix will report full-year earnings of ($1.72) per share for the current financial year, with EPS estimates ranging from ($1.84) to ($1.60). For the next year, analysts forecast that the company will post earnings of ($1.02) per share, with EPS estimates ranging from ($1.50) to ($0.75). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Ocular Therapeutix.
Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.01. The business had revenue of $0.83 million for the quarter, compared to analyst estimates of $1.09 million. Ocular Therapeutix had a negative net margin of 3,141.58% and a negative return on equity of 383.58%.
A number of equities analysts recently weighed in on OCUL shares. Zacks Investment Research upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Friday. JMP Securities reduced their target price on shares of Ocular Therapeutix from $9.00 to $7.00 and set a “market outperform” rating on the stock in a research note on Wednesday. HC Wainwright reissued a “buy” rating and issued a $6.00 target price (down previously from $9.00) on shares of Ocular Therapeutix in a research note on Friday. Piper Jaffray Companies reduced their price target on shares of Ocular Therapeutix from $8.00 to $5.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 12th. Finally, ValuEngine raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Ocular Therapeutix has a consensus rating of “Buy” and a consensus price target of $8.33.
Several hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new stake in Ocular Therapeutix during the third quarter worth about $32,000. Clear Harbor Asset Management LLC acquired a new stake in shares of Ocular Therapeutix in the third quarter valued at approximately $38,000. Creative Planning boosted its holdings in shares of Ocular Therapeutix by 37.8% in the third quarter. Creative Planning now owns 16,400 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 4,500 shares during the period. Highland Capital Management LLC acquired a new stake in shares of Ocular Therapeutix in the second quarter valued at approximately $62,000. Finally, Sio Capital Management LLC acquired a new stake in shares of Ocular Therapeutix during the second quarter worth $263,000. 49.38% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ OCUL traded up $0.13 during midday trading on Friday, hitting $2.80. The stock had a trading volume of 700,600 shares, compared to its average volume of 376,995. The business’s 50 day moving average is $3.21 and its 200-day moving average is $3.91. The company has a quick ratio of 6.39, a current ratio of 6.33 and a debt-to-equity ratio of 5.07. The company has a market cap of $128.37 million, a P/E ratio of -1.78 and a beta of 2.13. Ocular Therapeutix has a 52 week low of $2.35 and a 52 week high of $6.88.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery.
Featured Story: What is the LIBOR?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.